Who
Rahul D. Ballal
Director
Company insider
Files Form 4 as: Director, Agios Pharmaceuticals; Chief Executive Officer, Enliven Therapeutics.
In numbers
- Trades disclosed
- 78
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $3.7M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 14 Dec 2020
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,126 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,126 at $0.00 | filing |
| 11 Aug 2025filed 13 Aug 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,302 at $0.00 | filing |
| 11 Aug 2025filed 13 Aug 2025 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,302 at $0.00 | filing |
| 20 Jun 2025filed 23 Jun 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,120 at $0.00 | filing |
| 20 Jun 2025filed 23 Jun 2025 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,120 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,816 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,768 at $0.00 | filing |
| 6 Feb 2025filed 10 Feb 2025 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,491 at $0.00 | filing |
| 8 Nov 2024filed 12 Nov 2024 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 8 Nov 2024filed 12 Nov 2024 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $260K10,000 at $25.99 | filing |
| 8 Nov 2024filed 12 Nov 2024 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $204K3,571 at $57.24 | filing |
News
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearELVN · prnewswire.com · 14 Oct 2026Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist FinancialAGIO · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Rahul D. Ballal; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.